Toggling of NKG2A expression drives functional specialization of iPSC-derived CAR NK cells

Minoru Kanaya1, Camille Philippon1, Herman Netskar1,2

  • 1Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Insights

Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells show potent anti-cancer activity. These iNK cells mature independently of inhibitory receptor education, demonstrating strong effector functions for immunotherapy.

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Research

Background:

  • Induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells are a promising immunotherapy for hematological malignancies.
  • NK cell function is regulated by inhibitory receptors like CD94/NKG2A and KIR, but their role in iNK cell differentiation and education is unclear.

Purpose of the Study:

  • To investigate the acquisition and function of inhibitory receptors during iNK cell differentiation.
  • To determine the role of education by HLA-E in iNK cell maturation and function.

Main Methods:

  • Monitoring receptor repertoires, transcriptional states, and functional responses in engineered iNK cell lines.
  • Transcriptional reference mapping to compare iNK cells with peripheral blood NK cells.
  • CRISPR-Cas9 gene editing to knock out B2M and ablate NKG2A in iNK cells.

Main Results:

  • iNK cells exhibit a well-developed cytotoxic effector program and express high levels of Eomes, granzyme B, DNAM-1, and NKG2D.
  • NKG2A acquisition correlates with a more differentiated state and enhanced function, with attenuated inhibitory signaling.
  • NKG2A+ iNK cell potency is independent of HLA-E education; NKG2A ablation leads to compensatory NKG2C expression and enhanced cytotoxicity.

Conclusions:

  • iNK cells undergo education-independent functional maturation with potent effector programs.
  • iNK cells possess a favorable early-stage transcriptional profile for immunotherapy.
  • These findings support the potential of iNK cells as an off-the-shelf immunotherapy for hematological cancers.